Serum Institute conducting phase III clinical trial of BCG v
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The Serum Institute of India is conducting phase III clinical trial of BCG vaccine candidate VPM1002 for COVID-19 among high-risk persons of advanced age, comorbidities and high-exposure healthcare workers (HCWs), the Department of Biotechnology said in a statement.

About 6,000 individuals have been enrolled in a clinical trial to determine if the recombinant Bacillus Calmette-Guerian (rBCG) can boost immunity to fight against the virus, the statement added.

The objective of this trial is to evaluate the ability of VPM1002 in reducing infection incidence and severe disease outcomes of COVID-19 among high-risk persons of advanced age or co-morbidities and high-exposure healthcare workers (HCWs).

Renu Swarup, Secretary, DBT and Chairperson, BIRAC said the BCG vaccine is a proven platform and utilising its off-target effects for diseases other than TB is a very pragmatic approach to take.

"The trial began in May 2020 and has completed enrolment of 6,000 subjects in almost 40 hospitals across the country. This is an important milestone in the quest for preventing the disease and we look forward to the results of this important trial," she said.

Source: https://www.moneycontrol.com/news/business/serum-institute-conducting-phase-iii-clinical-trial-of-bcg-vaccine-dbt-5606841.html
Dr. R●●a P●●●l and 2 other likes this1 share
Like
Comment
Share